118 results on '"Engels, Eric A"'
Search Results
2. Cancers Attributable to Infections in the US in 2017: A Meta-Analysis
- Author
-
Volesky-Avellaneda, Karena D., Morais, Samantha, Walter, Stephen D., O’Brien, Thomas R., Hildesheim, Allan, Engels, Eric A., El-Zein, Mariam, and Franco, Eduardo L.
- Abstract
IMPORTANCE: Infections are largely modifiable causes of cancer. However, there remains untapped potential for preventing and treating carcinogenic infections in the US. OBJECTIVE: To estimate the percentage and number of incident cancers attributable to infections in the US among adults and children for the most recent year cancer incidence data were available (2017). DATA SOURCES: A literature search from 1946 onward was performed in MEDLINE on January 6, 2023, to obtain the data required to calculate population attributable fractions for 31 infection-cancer pairs. National Health and Nutrition Examination Survey data were used to estimate the population prevalence of hepatitis B and C viruses and Helicobacter pylori. STUDY SELECTION: Studies conducted in the US or other Western countries were selected according to specific infection-cancer criteria. DATA EXTRACTION AND SYNTHESIS: Data from 128 studies were meta-analyzed to obtain the magnitude of an infection-cancer association or prevalence of the infection within cancer cells. MAIN OUTCOMES AND MEASURES: The proportion of cancer incidence attributable to 8 infections. RESULTS: Of the 1 666 102 cancers diagnosed in 2017 among individuals aged 20 years or older in the US, 71 485 (4.3%; 95% CI, 3.1%-5.3%) were attributable to infections. Human papillomavirus (n = 38 230) was responsible for the most cancers, followed by H pylori (n = 10 624), hepatitis C virus (n = 9006), Epstein-Barr virus (n = 7581), hepatitis B virus (n = 2310), Merkel cell polyomavirus (n = 2000), Kaposi sarcoma–associated herpesvirus (n = 1075), and human T-cell lymphotropic virus type 1 (n = 659). Cancers with the most infection-attributable cases were cervical (human papillomavirus; n = 12 829), gastric (H pylori and Epstein-Barr virus; n = 12 565), oropharynx (human papillomavirus; n = 12 430), and hepatocellular carcinoma (hepatitis B and C viruses; n = 10 017). The burden of infection-attributable cancers as a proportion of total cancer incidence ranged from 9.6% (95% CI, 9.2%-10.0%) for women aged 20 to 34 years to 3.2% (95% CI, 2.4%-3.8%) for women aged 65 years or older and from 6.1% (95% CI, 5.2%-7.0%) for men aged 20 to 34 years to 3.3% (95% CI, 1.9%-4.4%) for men aged 65 years or older. Among those aged 19 years or younger, 2.2% (95% CI, 1.3%-3.0%) of cancers diagnosed in 2017 were attributable to Epstein-Barr virus. CONCLUSIONS AND RELEVANCE: Infections were estimated to be responsible for 4.3% of cancers diagnosed among adults in the US in 2017 and, therefore, represent an important target for cancer prevention efforts.
- Published
- 2023
- Full Text
- View/download PDF
3. Mosaic chromosomal alterations detected in men living with HIV and the relationship to non-Hodgkin lymphoma
- Author
-
Lin, Shu-Hong, Khan, Sairah M., Zhou, Weiyin, Brown, Derek W., Vergara, Candelaria, Wolinsky, Steven M., Martínez-Maza, Otoniel, Margolick, Joseph B., Martinson, Jeremy J., Hussain, Shehnaz K., Engels, Eric A., and Machiela, Mitchell J.
- Published
- 2023
- Full Text
- View/download PDF
4. Mortality among solid organ transplant recipients with a pretransplant cancer diagnosis
- Author
-
Hart, Allyson, Pfeiffer, Ruth M., Morawski, Bozena M., Lynch, Charles F., Zeng, Yun, Pawlish, Karen, Hurley, Deborah, Yu, Kelly J., and Engels, Eric A.
- Abstract
Little is known about the outcomes among solid organ transplant recipients with a pretransplant cancer diagnosis. We used linked data from the Scientific Registry of Transplant Recipients with 33 US cancer registries. Cox proportional hazards models assessed associations of pretransplant cancer with overall mortality, cancer-specific mortality, and development of a new posttransplant cancer. Among 311 677 recipients, the presence of a single pretransplant cancer was associated with increased overall mortality (adjusted hazard ratio [aHR], 1.19; 95% CI, 1.15-1.23) and cancer-specific mortality (aHR, 1.93; 95% CI, 1.76-2.12); results for 2+ pretransplant cancers were similar. Cancer-specific mortality was not significantly increased for uterine, prostate, or thyroid cancers (aHRs were 0.83, 1.22, and 1.54, respectively) but strongly elevated for lung cancer and myeloma (aHRs were 3.72 and 4.42, respectively). A pretransplant cancer diagnosis was also associated with increased risk of developing posttransplant cancer (aHR, 1.32; 95% CI, 1.23-1.40). Among 306 recipients whose cancer death was confirmed by cancer registry data, 158 deaths (51.6%) were from a de novo posttransplant cancer and 105 (34.3%) from the pretransplant cancer. Pretransplant cancer diagnoses are associated with increased mortality after transplantation, but some deaths are related to posttransplant cancers and other causes. Improved candidate selection and cancer screening and prevention may reduce mortality in this population.
- Published
- 2023
- Full Text
- View/download PDF
5. Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study
- Author
-
Haas, Cameron B, Engels, Eric A, Horner, Marie-Josèphe, Freedman, Neal D, Luo, Qianlai, Gershman, Susan, Qiao, Baozhen, Pfeiffer, Ruth M, and Shiels, Meredith S
- Abstract
Lung cancer is a common cancer in people living with HIV, but the risk of cancer in this group has not been investigated for over a decade. We investigated trends in relative and absolute risk of lung cancer among people living with HIV of various age groups in the USA.
- Published
- 2022
- Full Text
- View/download PDF
6. Cancer risk in living kidney donors
- Author
-
Engels, Eric A., Fraser, Gary E., Kasiske, Bertram L., Snyder, Jon J., Utt, Jason, Lynch, Charles F., Li, Jie, Pawlish, Karen S., Brown, Sandra, Yu, Kelly J., and Pfeiffer, Ruth M.
- Abstract
Living kidney donors are screened for transmissible diseases including cancer. Outcomes following donation are excellent, but concern exists regarding development of chronic kidney disease, and cancer risk is unknown. We used linked transplant and cancer registry data to identify incident cancers among 84,357 kidney donors in the United States (1995–2017). We compared risk with the general population using standardized incidence ratios (SIRs). For selected cancers, we used Poisson regression to compare donors with 47,451 Adventist Health Study 2 (AHS-2) participants, who typically have healthy lifestyles. During follow-up, 2843 cancers were diagnosed in donors, representing an overall deficit (SIR 0.79, 95%CI 0.76–0.82). None of 46 specified cancer sites occurred in excess relative to the general population, and 15 showed significant deficits (SIR < 1.00). Compared with AHS-2 participants, donors had similar incidence of liver cancer, melanoma, breast cancer, and non-Hodgkin lymphoma but, starting 7 years after donation, elevated incidence of colorectal cancer (adjusted incidence rate ratio 2.07, 95%CI 1.54–2.79) and kidney cancer (2.97, 1.58–5.58, accounting for the presence of a single kidney in donors). Elevated kidney cancer incidence may reflect adverse processes in donors’ remaining kidney. Nonetheless, cancer risk is lower than in the general population, suggesting that enhanced screening is unnecessary.
- Published
- 2022
- Full Text
- View/download PDF
7. Years of life lost to cancer among the United States HIV population, 2006–2015
- Author
-
Luo, Qianlai, Pfeiffer, Ruth M., Noone, Anne-Michelle, Horner, Marie-Josèphe, Engels, Eric A., and Shiels, Meredith S.
- Published
- 2022
- Full Text
- View/download PDF
8. Recent trends and future directions in human immunodeficiency virus-associated cancer
- Author
-
Shiels, Meredith S., Goedert, James J., and Engels, Eric A.
- Subjects
HIV infection -- Care and treatment ,HIV infection -- Forecasts and trends ,HIV infection -- Complications and side effects ,Cancer -- Demographic aspects ,Cancer -- Risk factors ,Highly active antiretroviral therapy -- Patient outcomes ,Market trend/market analysis ,Health - Published
- 2010
9. Age at cancer diagnosis among persons with AIDS in the United States
- Author
-
Shiels, Meredith S., Pfeiffer, Ruth M., and Engels, Eric A.
- Subjects
AIDS patients -- Diseases ,AIDS patients -- Medical examination ,Cancer -- Diagnosis ,Cancer -- Health aspects ,Cancer -- Methods ,Health - Abstract
Background: Studies have reported young ages at cancer diagnosis in HIV-infected persons and have suggested that HIV accelerates carcinogenesis. However, these comparisons did not account for differences in population age structures. Objective: To compare ages at diagnosis for non--AIDS-defining types of cancer that occur in both the AIDS and general populations, after adjustment for differences in age and other demographic characteristics between these populations. Design: Registry linkage study. Setting: 15 HIV/AIDS and cancer registry databases in the United States. Participants: 212 055 persons with AIDS enrolled in the U.S. HIV/ AIDS Cancer Match Study from 1996 to 2007. Measurements: Comparison of age-at-diagnosis distributions for various types of cancer in both the AIDS and general populations, after adjustment for age and other demographic characteristics. Results: The proportion of person-time contributed by older persons (age [greater than or equal to]65 years) was far smaller in the AIDS population (1.5%) than in the general population (12.5%). Reflecting this difference, the ages at diagnosis for most types of cancer were approximately 20 years younger among persons with AIDS. However, after adjustment for differences in the populations at risk, the median ages at diagnosis in the AIDS and general populations did not differ for most types of cancer (for example, colon, prostate, or breast cancer; all P > 0.100). In contrast, ages at diagnosis of lung (median, 50 vs. 54 years) and anal cancer (median, 42 vs. 45 years) were significantly younger in persons with AIDS than expected in the general population (P < 0.001), and the age at diagnosis of Hodgkin lymphoma was significantly older (median, 42 vs. 40 years; P < 0.001). Limitations: Information on other cancer risk factors, including cigarette smoking, was not available. Analysis was restricted to non-Hispanic white and black persons who had AIDS, which could limit the generalizability of the findings to other racial and ethnic groups or to persons with HIV but not AIDS. Conclusion: For most types of cancer, the age at diagnosis is similar in the AIDS and general populations, after adjustment for the ages of the populations at risk. Modest age differences remained for a few types of cancer, which may indicate either acceleration of carcinogenesis by HIV or earlier exposure to cancer risk factors. Primary Funding Source: National Cancer Institute.
- Published
- 2010
10. Spectrum of cancer risk late after AIDS onset in the United States
- Author
-
Simard, Edgar P., Pfeiffer, Ruth M., and Engels, Eric A.
- Subjects
Cancer -- Risk factors ,Cancer -- Demographic aspects ,Cancer -- Research ,AIDS (Disease) -- Care and treatment ,AIDS (Disease) -- Patient outcomes ,AIDS (Disease) -- Research ,Highly active antiretroviral therapy -- Influence ,Highly active antiretroviral therapy -- Research ,Health - Published
- 2010
11. Risk of human papillomavirus--associated cancers among persons with AIDS
- Author
-
Chaturvedi, Anil K., Madeleine, Margaret M., Biggar, Robert J., and Engels, Eric A.
- Subjects
Papillomavirus infections -- Risk factors ,Papillomavirus infections -- Health aspects ,AIDS (Disease) -- Research ,AIDS (Disease) -- Health aspects ,Cancer -- Diagnosis ,Immunosuppression -- Usage ,Health - Abstract
Background Although risk of human papillomavirus (HPV)-associated cancers of the anus, cervix, oropharynx, penis, vagina, and vulva is increased among persons with AIDS, the etiologic role of immunosuppression is unclear and incidence trends for these cancers over time, particularly after the introduction of highly active antiretroviral therapy in 1996, are not well described. Methods Data on 499 230 individuals diagnosed with AIDS from January 1, 1980, through December 31, 2004, were linked with cancer registries in 15 US regions. Risk of in situ and invasive HPV-associated cancers, compared with that in the general population, was measured by use of standardized incidence ratios (SIRs) and 95% confidence intervals (CIs). We evaluated the relationship of immunosuppression with incidence during the period of 4-60 months after AIDS onset by use of CD4 T-cell counts measured at AIDS onset. Incidence during the 4-60 months after AIDS onset was compared across three periods (1980-1989, 1990-1995, and 1996-2004). All statistical tests were two-sided. Results Among persons with AIDS, we observed statistically significantly elevated risk of all HPV-associated in situ (SIRs ranged from 8.9, 95% CI = 8.0 to 9.9, for cervical cancer to 68.6, 95% CI = 59.7 to 78.4, for anal cancer among men) and invasive (SIRs ranged from 1.6, 95% CI = 1.2 to 2.1, for oropharyngeal cancer to 34.6, 95% CI = 30.8 to 38.8, for anal cancer among men) cancers. During 1996-2004, low CD4 T-cell count was associated with statistically significantly increased risk of invasive anal cancer among men (relative risk [RR] per decline of 100 CD4 T cells per cubic millimeter = 1.34, 95% CI = 1.08 to 1.66, P = .006) and non-statistically significantly increased risk of in situ vagina or vulva cancer (RR = 1.52, 95% CI = 0.99 to 2.35, P= .055) and of invasive cervical cancer (RR = 1.32, 95% CI = 0.96 to 1.80, P= .077). Among men, incidence (per 100 000 person-years) of in situ and invasive anal cancer was statistically significantly higher during 1996-2004 than during 1990-1995 (61% increase for in situ cancers, 18.3 cases vs 29.5 cases, respectively; RR = 1.71, 95% CI = 1.24 to 2.35, P< .001; and 104% increase for invasive cancers, 20.7 cases vs 42.3 cases, respectively; RR = 2.03, 95% CI = 1.54 to 2.68, P < .001). Incidence of other cancers was stable over time. Conclusions Risk of HPV-associated cancers was elevated among persons with AIDS and increased with increasing immunosuppression. The increasing incidence for anal cancer during 1996-2004 indicates that prolonged survival may be associated with increased risk of certain HPV-associated cancers.
- Published
- 2009
12. Risk of immune thromocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection
- Author
-
Chiao, Elizabeth Y., Engels, Eric A., Kramer, Jennifer R., Pietz, Kenneth, Henderson, Louise, Giordano, Thomas P., and Landgren, Ola
- Subjects
Thrombocytopenic purpura -- Risk factors ,Thrombocytopenic purpura -- Demographic aspects ,Thrombocytopenic purpura -- Research ,Hemolytic anemia -- Risk factors ,Hemolytic anemia -- Demographic aspects ,Hemolytic anemia -- Research ,Hepatitis C -- Complications and side effects ,Hepatitis C -- Demographic aspects ,Hepatitis C -- Research ,Veterans -- Health aspects ,Veterans -- Research ,Health - Published
- 2009
13. Spectrum of Nonkeratinocyte Skin Cancer Risk Among Solid Organ Transplant Recipients in the US
- Author
-
Sargen, Michael R., Cahoon, Elizabeth K., Yu, Kelly J., Madeleine, Margaret M., Zeng, Yun, Rees, Judy R., Lynch, Charles F., and Engels, Eric A.
- Abstract
IMPORTANCE: Nonkeratinocyte skin cancers are an important cause of morbidity and mortality for immunosuppressed solid organ transplant recipients (SOTRs), but the spectrum of disease and risk factor characteristics are unknown. OBJECTIVE: To characterize the spectrum of disease and risk factors for common and rare nonkeratinocyte skin cancers in SOTRs. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study included 444 497 SOTRs who underwent a transplant in the US between January 1, 1987, and December 31, 2017, using linked data from the national transplant registry and 32 cancer registries. Data analysis was conducted from April 1, 2021, to September 30, 2021. MAIN OUTCOMES AND MEASURES: Standardized incidence ratios (SIRs) were used to assess risk relative to the general population, and Poisson regression was used to evaluate risk factors. RESULTS: A total of 2380 nonkeratinocyte skin cancers were identified among 444 497 SOTRs (median age at transplant, 50 years; range, 0-96 years; 274 276 [61.7%] male; 272 241 [61.2%] non-Hispanic White). Melanoma was the most common cancer (1471 [61.8%]), followed by Merkel cell carcinoma (334 [14.0%]), Kaposi sarcoma (186 [7.8%]), sebaceous carcinoma (170 [7.1%]), and cutaneous lymphomas (108 [4.5%]). Risks were most strongly elevated for cancers associated with viruses, including Kaposi sarcoma (SIR, 20.5; 95% CI, 17.7-23.7), Merkel cell carcinoma (SIR, 16.2; 95% CI, 14.5-18.1), and extranodal natural killer/T-cell lymphoma (SIR, 44.3; 95% CI, 5.37-160). Risks were also significantly elevated for sebaceous carcinoma (SIR, 15.2; 95% CI, 13.0-17.7), anaplastic large cell lymphoma (SIR, 6.82; 95% CI, 4.53-9.85), and diffuse large B-cell lymphoma (SIR, 5.17; 95% CI, 3.28-7.76). Several characteristics were independently associated with greater risk for multiple skin cancer types, including male sex, older age at transplant, factors associated with UV radiation exposure (non-Hispanic White race and ethnicity, living in an area with higher UV radiation exposure, and posttransplant diagnosis of keratinocyte carcinoma), and increasing time since transplantation. Treatment with mammalian target of rapamycin inhibitors was associated with reduced melanoma incidence (incidence rate ratio, 0.75; 95% CI, 0.57-0.98). A total of 847 skin cancers (39.4%) occurred on the head and neck. CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that viruses, UV radiation exposure, and immunosuppression are associated with the development of skin cancer in SOTRs. Certain high-risk subgroups may benefit from increased skin surveillance, and treatment with mammalian target of rapamycin inhibitors could be effective for melanoma chemoprevention in the transplant population.
- Published
- 2022
- Full Text
- View/download PDF
14. Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial
- Author
-
Yu, Ying-Ying, Pinsky, Paul F., Caporaso, Neil E., Chatterjee, Nilanjan, Baumgarten, Mona, Langenberg, Patricia, Furuno, Jon P., Lan, Qing, and Engels, Eric A.
- Subjects
Cicatrices -- Research ,Cicatrices -- Physiological aspects ,Lung cancer -- Risk factors ,Radiography -- Usage ,Cancer -- Diagnosis ,Cancer -- Research ,Health - Published
- 2008
15. Chronic immune stimulation and subsequent Waldenstrom macroglobulinemia
- Author
-
Koshiol, Jill, Gridley, Gloria, Engels, Eric A., McMaster, Mary L., and Landgren, Ola
- Subjects
Macroglobulinemia -- Risk factors ,Macroglobulinemia -- Research ,Autoimmune diseases -- Research ,Health - Published
- 2008
16. Cancer risk among HIV-exposed uninfected children in the United States
- Author
-
Horner, Marie-Josèphe, Hazra, Rohan, Barnholtz-Sloan, Jill S., Shiels, Meredith S., and Engels, Eric A.
- Published
- 2023
- Full Text
- View/download PDF
17. Second cancers among 104760 survivors of cervical cancer: evaluation of long-term risk
- Author
-
Chaturvedi, Anil K., Engels, Eric A., Gilbert, Ethel S., Chen, Bingshu E., Storm, Hans, Lynch, Charles F., Hall, Per, Langmark, Froydis, Pukkala, Eero, Kaijser, Magnus, Andersson, Michael, Fossa, Sophie D., Joensuu, Heikki, Boice, John D., Kleinerman, Ruth A., and Travis, Lois B.
- Subjects
Cervical cancer -- Risk factors ,Cancer survivors -- Health aspects ,Cancer survivors -- Physiological aspects ,Radiotherapy -- Complications and side effects ,Diseases -- Relapse ,Diseases -- Risk factors ,Health - Abstract
Background Given the extended survival of patients diagnosed with cervical cancer, the large number of these women treated with radiotherapy, and the presence in this population of established cancer risk factors such as human papillomavirus (HPV) infection and cigarette smoking, it is important to clarify long-term trends in second cancer risk. Methods Using data from 104760 one-year survivors of cervical cancer reported to 13 population-based cancer registries in Denmark, Finland, Norway, Sweden, and the United States, we calculated standardized incidence ratios (SIRs) for second cancers overall and cancers at particular sites among women with cervical cancer, including cervical cancer patients who were treated or not treated with radiation, over more than 40 years of follow-up. Cox regression models were used to assess the time-varying association of radiotherapy with risk of second cancers and to assess the interaction of radiation treatment with age at diagnosis. All statistical tests were two-sided. Results Among 104760 one-year survivors of cervical cancer, the risk of all second cancers taken together was increased to a statistically significant extent (n = 12496; SIR = 1.30; 95% confidence interval [CI] = 1.28 to 1.33). Compared with the general population, in both radiotherapy (N = 52613) and no-radiotherapy groups (N = 27382), risks for HPV-related cancers (of the pharynx, genital sites, and rectum/anus) and smoking-related cancers (of the pharynx, trachea/bronchus/lung, pancreas, and urinary bladder) were elevated to a statistically significant extent. Cervical cancer patients treated with radiotherapy, but not those who did not receive radiotherapy, were at increased risk for all second cancers and cancers at heavily irradiated sites (colon, rectum/anus, urinary bladder, ovary, and genital sites) beyond 40 years of follow-up compared with women in the general population. The association of radiotherapy with second cancer risk was modified by age at cervical cancer diagnosis for rectum/anus, genital sites, and urinary bladder, with higher hazard ratios for second cancer at younger ages of cervical cancer. After adjustment for competing mortality, the 40-year cumulative risk of any second cancer was higher among women diagnosed with cervical cancer before age 50 (22.2%; 95% CI = 21.5% to 22.8%) than among women diagnosed after age 50 (16.4%; 95% CI = 16.1% to 16.9%). Conclusion Cervical cancer patients treated with radiotherapy are at increased risk of second cancers at sites in close proximity to the cervix beyond 40 years of follow-up. J Natl Cancer Inst 2007;99:1634-43
- Published
- 2007
18. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission
- Author
-
Engels, Eric A., Atkinson, Jonnae O., Graubard, Barry I., McQuillan, Geraldine M., Gamache, Christine, Mbisa, Georgina, Cohn, Silvia, Whitby, Denise, and Goedert, James J.
- Subjects
Human herpesvirus 8 -- Diagnosis ,Human herpesvirus 8 -- Development and progression ,Human herpesvirus 8 -- Demographic aspects ,Human herpesvirus 8 -- Risk factors ,Gay men -- Risk factors ,Gay men -- Sexual behavior ,Sexually transmitted diseases -- Research ,Health - Published
- 2007
19. AIDS-Related Cancer and Severity of Immunosuppression in Persons With AIDS
- Author
-
Biggar, Robert J., Chaturvedi, Anil K., Goedert, James J., and Engels, Eric A.
- Subjects
AIDS (Disease) -- Complications and side effects ,Immunosuppression -- Causes of ,Immunosuppression -- Research ,Cancer -- Development and progression ,Cancer -- Care and treatment ,Health - Abstract
Background The incidence of Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer has been declining among persons with AIDS. We investigated the association between cancer risk and CD4 cell count among such persons. Methods Data from US AIDS registries were linked to local cancer registry data. Cancer incidence per 100000 person-years was determined for the 4-27 months from the onset of AIDS from January 1, 1990, through December 31, 1995--before highly active antiretroviral therapy (HAART) became available--and from January 1, 1996, through December 31, 2002. The relationships between CD4 count at AIDS onset and cancer incidence were assessed by proportional hazards models. Results Among 325516 adults with AIDS, the incidence of Kaposi sarcoma was lower in 1996-2002 (334.6 cases per 100 000 person-years) than in 1990-1995 (1838.9 cases per 100 000 person-years), and the incidence of non-Hodgkin lymphoma followed a similar pattern (i.e., 390.1 cases per 100 000 person-years in 1996-2002 and 1066.2 cases per 100 000 person-years in 1990-1995). In 1996-2002, for each decline in CD4 cell count of 50 cells per microliter of blood, increased risks were found for Kaposi sarcoma (hazard ratio [HR] = 1.40, 95% confidence interval [CI]=1.33 to 1.50), for central nervous system non-Hodgkin lymphoma subtypes (HR = 1.85, 95% CI = 1.58 to 2.16), and for non-central nervous system diffuse large B-cell lymphoma (HR = 1.12, 95% CI = 1.04 to 1.20) but not for non-central nervous system Burkitt lymphoma (HR = 0.93, 95% CI = 0.81 to 1.06). Cervical cancer incidence was higher in 1996-2002 (86.5 per 100 000 person-years) than in 1990-1995 (64.2 per 100 000 person-years), although not statistically significantly so (relative risk [RR] = 1.41, 95% CI = 0.81 to 2.46). After adjustment for age, race, and sex or mode of HIV exposure, the risks for Kaposi sarcoma (RR = 0.22, 95% CI = 0.20 to 0.24) and for non-Hodgkin lymphoma (RR = 0.40, 95% CI = 0.36 to 0.44) were lower in the period of 1996-2002 than in 1990-1995. Similar relationships of these cancers to CD4 count were observed for 1990-1995. Conclusions Both before and after HAART was available, CD4 count was strongly associated with risks for Kaposi sarcoma and non-Hodgkin lymphoma but not for cervical cancer and Burkitt lymphoma. The decreasing incidences of most AIDS-associated cancers in persons with AIDS during the 1990s are consistent with improving CD4 counts after HAART introduction in 1996.
- Published
- 2007
20. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia
- Author
-
Landgren, Ola, Engels, Eric A., Pfeiffer, Ruth M., Gridley, Gloria, Mellemkjaer, Lene, Olsen, Jorgen H., Kerstann, Kimberly F., Wheeler, William, Hemminki, Kari, Linet, Martha S., and Goldin, Lynn R.
- Subjects
Autoimmune diseases -- Risk factors ,Autoimmune diseases -- Diagnosis ,Autoimmune diseases -- Care and treatment ,Autoimmunity -- Health aspects ,Health - Abstract
Background: Personal history of autoimmune diseases is consistently associated with increased risk of non-Hodgkin lymphoma. In contrast, there are limited data on risk of Hodgkin lymphoma following autoimmune diseases and almost no data addressing whether there is a familial association between the conditions. Methods: Using population-based linked registry data from Sweden and Denmark, 32 separate autoimmune and related conditions were identified from hospital diagnoses in 7476 case subjects with Hodgkin lymphoma, 18 573 matched control subjects, and more than 86 000 first-degree relatives of case and control subjects. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) as measures of relative risks for each condition using logistic regression and also applied multivariable hierarchical regression models. All P values are two-sided. Results: We found statistically significantly increased risks of Hodgkin lymphoma associated with personal histories of several autoimmune conditions, including rheumatoid arthritis (OR = 2.7, 95% CI = 1.9 to 4.0), systemic lupus erythematosus (OR = 5.8, 95% CI = 2.2 to 15.1), sarcoidosis (OR = 14.1, 95% CI = 5.4 to 36.8), and immune thrombocytopenic purpura (OR = [infinity], P = .002). A statistically significant increase in risk of Hodgkin lymphoma was associated with family histories of sarcoidosis (OR = 1.8, 95% CI = 1.01 to 3.1) and ulcerative colitis (OR = 1.6, 95% CI = 1.02 to 2.6). Conclusions: Personal or family history of certain autoimmune conditions was strongly associated with increased risk of Hodgkin lymphoma. The association between both personal and family histories of sarcoidosis and a statistically significantly increased risk of Hodgkin lymphoma suggests shared susceptibility for these conditions.
- Published
- 2006
21. Molecular evidence for mother-to-child transmission of Kaposi Sarcoma-associated herpesvirus in Uganda and K1 gene evolution within the host
- Author
-
Mbulaiteye, Sam, Marshall, Vickie, Bagni, Rachel K., Wang, Cheng-Dian, Mbisa, Georgina, Bakaki, Paul M., Owor, Anchilla M., Ndugwa, Christopher M., Engels, Eric A., Katongole-Mbidde, Edward, Biggar, Robert J., and Whitby, Denise
- Subjects
Kaposi's sarcoma -- Research ,Kaposi's sarcoma -- Physiological aspects ,Disease transmission -- Research ,Disease transmission -- Physiological aspects ,Herpesviruses -- Physiological aspects ,Herpesviruses -- Research ,Health - Published
- 2006
22. High levels of Epstein-Barr virus DNA in saliva and peripheral blood from Ugandan mother-child pairs
- Author
-
Mbulaiteye, Sam M., Walters, Michael, Engels, Eric A., Bakaki, Paul M., Ndugwa, Christopher M., Owor, Anchilla M., Goedert, James J., Whitby, Denise, and Biggar, Robert J.
- Subjects
Salivary glands -- secretions ,Burkitt's lymphoma ,DNA ,Epstein-Barr virus ,Saliva ,Health - Published
- 2006
23. Serologic evidence for exposure to simian virus 40 in North American zoo workers
- Author
-
Engels, Eric A., Switzer, William M., Heneine, Walid, and Viscidi, Raphael P.
- Subjects
Communicable diseases -- Risk factors ,Communicable diseases -- Care and treatment ,Simian viruses -- Risk factors ,Health - Published
- 2004
24. Detection of Kaposi sarcoma-associated herpesvirus DNA in saliva and buffy-coat samples from children with sickle cell disease in Uganda
- Author
-
Mbulaiteye, Sam M., Pfeiffer, Ruth M., Engels, Eric A., Marshall, Vickie, Bakaki, Paul M., Owor, Anchilla M., Ndugwa, Christopher M., Katongole-Mbidde, Edward, Goedert, James J., Biggar, Robert J., and Whitby, Denise
- Subjects
Sickle cell anemia -- Research ,Herpesvirus diseases -- Diagnosis ,Herpesvirus diseases -- Research ,Herpes -- Diagnosis ,Herpes -- Research ,Children -- Health aspects ,Health - Published
- 2004
25. Case-control study of simian virus 40 and non-Hodgkin lymphoma in the United States
- Author
-
Engels, Eric A., Viscidi, Raphael P., Galloway, Denise A., Carter, Joseph J., Cerhan, James R., Davis, Mac, Cozen, Wendy, Severson, Richard K., de Sanjose, Silvia, Colt, Joanne S., and Hartge, Patricia
- Subjects
Hodgkin's disease -- Research ,SV40 (Virus) -- Research ,Health - Abstract
Background: Recent studies have reported detection of simian virus 40 (SV40) DNA in tumor tissues from 15%-43% of U.S. non-Hodgkin lymphoma (NHL) patients. SV40 accidentally contaminated U.S. poliovirus vaccines that were widely administered from 1955 through 1962. However, epidemiologic data linking SV40 with NHL are lacking. Methods: We obtained serum samples from 724 incident NHL case patients and 622 control subjects from a population-based U.S. case-control study. SV40 serostatus was analyzed by two independent laboratories (designated A and B) using similar virus-like particle (VLP) enzyme immunoassays. Associations with serostatus were assessed with logistic regression, adjusting for sex, race, birth year, and study site. VLPs for the human polyomaviruses BK and JC were used in competitive inhibition experiments to assess the specificity of SV40 reactivity. Statistical tests were two-sided. Results: SV40 antibody results from the two laboratories were correlated (R = 0.59; P
- Published
- 2004
26. Human herpesvirus 8 infection and transfusion history in children with sickle-cell disease in Uganda
- Author
-
Mbulaiteye, Sam M., Biggar, Robert J., Bakaki, Paul M., Pfeiffer, Ruth M., Whitby, Denise, Owor, Anchilla M., Katongole-Mbidde, Edward, Goedert, James J., Ndugwa, Christopher M., and Engels, Eric A.
- Subjects
Blood transfusion -- Health aspects ,Sickle cell anemia -- Complications ,Communicable diseases -- Risk factors ,Human herpesvirus 8 -- Physiological aspects ,Health - Abstract
Background: Although human herpesvirus 8 (HHV-8), the etiologic agent for Kaposi's sarcoma, can be detected in peripheral blood, blood-borne transmission of this virus has not been demonstrated. We studied the association between HHV-8 seropositivity and transfusion history among children with sickle-cell disease in Uganda, where HHV-8 infection is common in blood donors. Methods: We studied 600 children (aged 0-16 years) with sickle-cell disease at Mulago Hospital, Kampala, from November 2001 through April 2002. By design, about half had previously been transfused. HHV-8 serostatus was determined using enzyme-linked immunosorbent assays for antibodies against HHV-8 proteins K8.1 and orf73. We used logistic regression to test for an association between HHV-8 serostatus and transfusion history and a Markov model to estimate the transmission risk per transfusion and the cumulative risk from community (i.e., nontransfusion) sources. Statistical tests were two-sided. Results: HHV-8 antibodies were detected in 117 of 561 (21%) children with unambiguous K8.1 results. HHV-8 seroprevalence among the never-transfused children increased with age from 7% in children aged 0-2 years to 32% in those aged 13-16 years ([P.sub.trend]
- Published
- 2003
27. Cancer incidence in Denmark following exposure to poliovirus vaccine contaminated with simian virus 40
- Author
-
Engels, Eric A., Katki, Hormuzd A., Nielsen, Nete M., Winther, Jeanette F., Hjalgrim, Henrik, Gjerris, Flemming, Rosenberg, Philip S., and Frisch, Morten
- Subjects
Poliomyelitis vaccine -- Adverse and side effects ,Cancer -- Demographic aspects ,Cancer -- Risk factors ,Disease susceptibility -- Research ,Cancer in children -- Risk factors ,Health - Abstract
Background: Early poliovirus vaccines were accidentally contaminated with simian virus 40 (SV40). In Denmark, poliovirus vaccine was administered to most children from 1955 through 1961. SV40 DNA sequences have been detected in several human malignancies, including mesothelioma, ependymoma, choroid plexus tumors, and non-Hodgkin's lymphoma. To clarify whether SV40 infection increases risk of these cancers or of cancers arising in children, we examined cancer incidence in three Danish birth cohorts. Methods: Population-based cancer incidence data from 1943 through 1997 were obtained from the Danish Cancer Registry. The relationship between exposure to SV40-contaminated vaccine and cancer incidence was evaluated by examining incidence in birth cohorts that differed in exposure to SV40-contaminated vaccine. In addition, cancer incidence was examined in children who were 0-4 years of age before, during, and after the period of vaccine contamination. Incidence was compared using Poisson regression, adjusting for age differences. All statistical tests were two-sided. Results: After 69.5 million person-years of follow-up, individuals exposed to SV40-contaminated poliovirus vaccine as infants (i.e., born 1955-1961) or children (i.e., born 1946-1952) had lower overall cancer risk (age-adjusted relative risk [RR] = 0.86, 95% confidence interval [CI] = 0.81 to 0.91 and RR = 0.79, 95% CI = 0.75 to 0.84, respectively; P
- Published
- 2003
28. Antibody reactivity to latent and lytic antigens to human herpesvirus--8 in longitudinally followed homosexual men. (Major Article)
- Author
-
Biggar, Robert J., Engels, Eric A., Whitby, Denise, Kedes, Dean H., and Goedert, James J.
- Subjects
Gays -- Physiological aspects ,Human herpesvirus 8 -- Physiological aspects ,Antigen-antibody reactions -- Analysis ,Health - Published
- 2003
29. Typhoid fever vaccines:a meta-analysis of studies on efficacy and toxicity
- Author
-
Engels, Eric A., Falagas, Matthew E., Lau, Joseph, and Bennish, Michael L.
- Subjects
Typhoid vaccine -- Complications and side effects ,Vaccines -- Evaluation -- Complications and side effects ,Typhoid fever -- Prevention -- Complications and side effects ,Health ,Evaluation ,Prevention ,Complications and side effects - Abstract
Abstract Objective: To estimate the efficacy and toxicity of typhoid fever vaccines. Design: Meta-analysis of randomised efficacy trials and both randomised and non-randomised toxicity studies of the parenteral whole cell, [...]
- Published
- 1998
30. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection
- Author
-
Zekavat, Seyedeh M., Lin, Shu-Hong, Bick, Alexander G., Liu, Aoxing, Paruchuri, Kaavya, Wang, Chen, Uddin, Md Mesbah, Ye, Yixuan, Yu, Zhaolong, Liu, Xiaoxi, Kamatani, Yoichiro, Bhattacharya, Romit, Pirruccello, James P., Pampana, Akhil, Loh, Po-Ru, Kohli, Puja, McCarroll, Steven A., Kiryluk, Krzysztof, Neale, Benjamin, Ionita-Laza, Iuliana, Engels, Eric A., Brown, Derek W., Smoller, Jordan W., Green, Robert, Karlson, Elizabeth W., Lebo, Matthew, Ellinor, Patrick T., Weiss, Scott T., Daly, Mark J., Terao, Chikashi, Zhao, Hongyu, Ebert, Benjamin L., Reilly, Muredach P., Ganna, Andrea, Machiela, Mitchell J., Genovese, Giulio, and Natarajan, Pradeep
- Abstract
Age is the dominant risk factor for infectious diseases, but the mechanisms linking age to infectious disease risk are incompletely understood. Age-related mosaic chromosomal alterations (mCAs) detected from genotyping of blood-derived DNA, are structural somatic variants indicative of clonal hematopoiesis, and are associated with aberrant leukocyte cell counts, hematological malignancy, and mortality. Here, we show that mCAs predispose to diverse types of infections. We analyzed mCAs from 768,762 individuals without hematological cancer at the time of DNA acquisition across five biobanks. Expanded autosomal mCAs were associated with diverse incident infections (hazard ratio (HR) 1.25; 95% confidence interval (CI) = 1.15–1.36; P= 1.8 × 10−7), including sepsis (HR 2.68; 95% CI = 2.25–3.19; P= 3.1 × 10−28), pneumonia (HR 1.76; 95% CI = 1.53–2.03; P= 2.3 × 10−15), digestive system infections (HR 1.51; 95% CI = 1.32–1.73; P= 2.2 × 10−9) and genitourinary infections (HR 1.25; 95% CI = 1.11–1.41; P= 3.7 × 10−4). A genome-wide association study of expanded mCAs identified 63 loci, which were enriched at transcriptional regulatory sites for immune cells. These results suggest that mCAs are a marker of impaired immunity and confer increased predisposition to infections.
- Published
- 2021
- Full Text
- View/download PDF
31. Cure models, survival probabilities, and solid organ transplantation for patients with colorectal cancer
- Author
-
Engels, Eric A., Mandal, Soutrik, Corley, Douglas A., Blosser, Christopher D., Hart, Allyson, Lynch, Charles F., Qiao, Baozhen, Pawlish, Karen S., Haber, Gregory, Yu, Kelly J., and Pfeiffer, Ruth M.
- Abstract
A previous cancer diagnosis can preclude patients from consideration for solid organ transplantation. Statistical models may improve candidate selection. We fitted statistical cure models and estimated 5-year cancer-specific survival (5yCSS) for colorectal cancer patients in the United States using registry data. The median cure probability at cancer diagnosis for patients in the general population was 0.67. Among 956 colorectal cancer patients who underwent solid organ transplantation, the median time since diagnosis was 6.3 years and the median 5yCSS at transplantation was 0.96. Patients with a 5yCSS below 0.90 had increased posttransplant cancer-specific mortality (hazard ratio 3.31, 95% CI 1.52-7.21). Compared with recently published guidelines, our models suggested shorter wait times for some groups of colorectal cancer patients (eg, stage IIA cancers) and longer wait times for others (stages IIB, IIIB, IIIC, IV). In conclusion, colorectal cancer patients undergoing solid organ transplantation had excellent prognoses, reflecting selection incorporating existing guidelines and clinical judgment. Nonetheless, 5yCSS probabilities estimated from cure models offer additional prognostic information for patients considered for transplantation and identify situations where current guidelines might be revised. We developed a web-based tool for clinicians to calculate 5yCSS probabilities for use in transplant evaluation for individual colorectal cancer patients (https://dceg.cancer.gov/tools/risk-assessment/calculator-of-colorectal-cancer-survival-probability).
- Published
- 2024
- Full Text
- View/download PDF
32. Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry
- Author
-
Schonfeld, Sara J., Valcarcel, Bryan, Meyer, Christa L., Shaw, Bronwen E., Phelan, Rachel, Rizzo, J. Douglas, Brunson, Ann, Cooley, Julianne J. P., Abrahão, Renata, Wun, Ted, Gadalla, Shahinaz M., Engels, Eric, Albert, Paul S., Yusuf, Rafeek, Spellman, Stephen R., Curtis, Rochelle E., Auletta, Jeffery J., Muffly, Lori, Keegan, Theresa H. M., and Morton, Lindsay M.
- Abstract
•Linkage of CIBMTR with cancer registry data leads to more complete estimates of cumulative incidence of solid neoplasms following HCT.•This collaborative approach can improve risk factor evaluation to help inform follow-up care practice in the growing HCT survivor population.
- Published
- 2024
- Full Text
- View/download PDF
33. Outcomes in solid organ transplant recipients with a pretransplant diagnosis of melanoma
- Author
-
Zwald, Fiona O., Sargen, Michael R., Austin, April A., Hsieh, Mei-Chin, Pawlish, Karen, Li, Jie, Lynch, Charles F., Yu, Kelly J., and Engels, Eric A.
- Abstract
Melanoma causes significant morbidity in solid organ transplant recipients (SOTRs). Melanomas diagnosed before transplantation can recur with intensive immunosuppression, but outcomes have not been well studied. We evaluated 901 non-Hispanic White SOTRs with a pretransplant melanoma identified using linked transplant and cancer registry data in the United States. Most pretransplant melanomas were invasive (60.7%), and the median time from diagnosis to transplantation was 5.1 years. After transplantation, 41 SOTRs developed a new invasive melanoma, corresponding to 9-fold increased risk compared with the general population (standardized incidence ratio 9.2, 95% confidence interval [CI] 6.6-12). Twenty-two SOTRs died from melanoma after transplantation, corresponding to 52-fold increased risk (standardized mortality ratio 52, 95% CI 33-79). Risk factors for posttransplant melanoma included age at transplantation (adjusted hazard ratio [HR] 2.86, 95% CI 1.24-6.60 for age 55+ vs. <55 years) and maintenance immunosuppression with cyclosporine/azathioprine (adjusted HR 2.53, 95% CI 1.08-5.90). Melanoma mortality was strongly elevated after a posttransplant melanoma diagnosis (HR 35.6, 95% CI 14.0-90.4, adjusted for cyclosporine/azathioprine maintenance therapy and calendar year of transplantation). In conclusion, SOTRs with a pretransplant melanoma are at risk of adverse melanoma-related outcomes after transplantation. These findings support thorough dermatologic evaluation prior to transplantation and frequent posttransplant surveillance.
- Published
- 2024
- Full Text
- View/download PDF
34. Sebaceous Carcinoma Incidence and Survival Among Solid Organ Transplant Recipients in the United States, 1987-2017
- Author
-
Sargen, Michael R., Cahoon, Elizabeth K., Lynch, Charles F., Tucker, Margaret A., Goldstein, Alisa M., and Engels, Eric A.
- Abstract
IMPORTANCE: Risk of sebaceous carcinoma (SC), a rare skin cancer associated with Muir-Torre syndrome, is elevated among solid organ transplant recipients (SOTRs). However, population studies evaluating this association and assessing survival for posttransplant cases are lacking, and further understanding of SC epidemiology in this immunosuppressed population could provide etiologic and clinical insights. OBJECTIVE: To assess SC incidence and patient survival after solid organ transplantation. DESIGN, SETTING, AND PARTICIPANTS: This cohort study, conducted from January 1, 1987, to December 31, 2017, used data from the Transplant Cancer Match Study, which links transplant and cancer registry data for 17 states and 1 metropolitan area in the United States. Altogether, these registries account for approximately 46% of all US transplants. Data on demographic and transplant characteristics as well as induction and initial maintenance immunosuppressive therapies were obtained from the transplant registry. Standardized incidence ratios (SIRs) comparing SC incidence among SOTRs to the general population were calculated. Incidence rate ratios (IRRs) comparing SC risk between SOTR subgroups were calculated using multivariate Poisson regression. Cox regression was used to compare overall survival between SC cases in SOTRs and other individuals. MAIN OUTCOMES AND MEASURES: Sebaceous carcinoma incidence and overall patient survival after transplantation compared with the general population. RESULTS: A total of 326 282 transplant procedures were performed for 301 075 patients (No. [%] age at transplant, 126 550 [38.8%] aged 0-44 years; 82 394 [25.3%] aged 45-54 years; 82 082 [25.5%] aged 55-64 years; 35 256 [10.8%] aged ≥65 years; 201 354 male patients [61.7%]; 202 557 White patients [62.1%]). A total of 102 SCs were diagnosed in 301 075 SOTRs, corresponding to a 25-fold increased incidence (SIR, 24.8; 95% CI, 20.2-30.1). Incidence was especially elevated among lung recipients (SIR, 47.7; 95% CI, 20.6-94.0) and after a posttransplant diagnosis of cutaneous squamous cell carcinoma (SIR, 104.0; 95% CI, 62.8-163.0). Among SOTRs, factors independently associated with SC risk included male sex (IRR, 2.46; 95% CI, 1.48-4.07; P < .001), race/ethnicity (non-Hispanic Black vs non-Hispanic White, IRR, 0.28; 95% CI, 0.10-0.77; P = .01), older age (IRR, 7.85; 95% CI, 3.85-16.0; ≥65 vs 0-44 years; P < .001 for trend), use of thymoglobulin induction (IRR, 1.82; 95% CI, 1.16-2.86; P = .009), posttransplant cutaneous squamous cell carcinoma (IRR, 4.60; 95% CI, 2.67-7.94; P < .001), and longer time since transplant (IRR, 8.40; 95% CI, 3.94-17.90; ≥10 vs 0-1.9 years; P < .001 for trend). Muir-Torre syndrome–associated cancers were rare among both SOTRs and others with SC (3.3%-4.1%). Among patients with SC, prior transplantation was associated with increased overall mortality (adjusted hazard ratio, 2.09; 95% CI, 1.45-3.01), although few deaths were attributed to SC (4 of 92 SOTRs [4.3%]; 235 of 3585 non-SOTRs [6.6%]). CONCLUSIONS AND RELEVANCE: Among SOTRs, results of this large cohort study suggest that SC was associated with measures of immunosuppression, and overall survival was worse than for other patients with SC. Findings also suggest a possible role for UV radiation in carcinogenesis.
- Published
- 2020
- Full Text
- View/download PDF
35. Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States
- Author
-
D’Arcy, Monica E., Pfeiffer, Ruth M., Rivera, Donna R., Hess, Gregory P., Cahoon, Elizabeth K., Arron, Sarah T., Brownell, Isaac, Cowen, Edward W., Israni, Ajay K., Triplette, Matthew A., Yanik, Elizabeth L., and Engels, Eric A.
- Abstract
IMPORTANCE: The antifungal medication voriconazole is used to prevent and treat aspergillosis, a major cause of mortality among recipients of lung transplants (hereinafter referred to as lung recipients). Small studies suggest that voriconazole increases risk of cutaneous squamous cell carcinoma (SCC). OBJECTIVE: To examine associations of voriconazole and other antifungal medications with risk of keratinocyte carcinomas (SCC and cutaneous basal cell carcinoma [BCC]) in lung recipients. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study included non-Hispanic white patients (n = 9599) who underwent lung transplant in the United States from January 1, 2007, to December 31, 2016, identified through the national Scientific Registry of Transplant Recipients with data linkable to pharmacy claims. Data were analyzed from March 1, 2018, to February 13, 2019. EXPOSURES: Antifungal medication use, including voriconazole, itraconazole, posaconazole, and other antifungals, was ascertained from pharmacy claims and treated as a time-varying exposure (assessed every 30 days). Cumulative antifungal exposure was calculated as the total number of exposed months. MAIN OUTCOMES AND MEASURES: Primary outcomes were the first SCC or BCC reported to the transplant registry by transplant centers. Follow-up began at transplant and ended at SCC or BCC diagnosis, transplant failure or retransplant, death, loss to follow-up, or December 31, 2016. Cox proportional hazards regression models were used to estimate adjusted hazard ratios (AHRs) for each antifungal medication. RESULTS: Among the 9793 lung transplants in 9599 recipients included in the analysis, median age at transplant was 59 (interquartile range [IQR], 48-65) years, 5824 (59.5%) were male, and 5721 (58.4%) reported ever smoking. During a median follow-up of 3.0 (IQR, 1.4-5.0) years after transplant, 1031 SCCs (incidence, 322 per 10 000 person-years) and 347 BCCs (incidence, 101 per 10 000 person-years) were reported. Compared with lung recipients with no observed voriconazole use, those with 1 to 3 months of voriconazole use experienced increased AHR for SCC of 1.09 (95% CI, 0.90-1.31); 4 to 7 months, 1.42 (95% CI, 1.16-1.73); 8 to 15 months, 2.04 (95% CI, 1.67-2.50); and more than 15 months, 3.05 (95% CI, 2.37-3.91). Ever itraconazole exposure was associated with increased SCC risk (AHR, 1.20; 95% CI, 1.00-1.45). For BCC, risk was not associated with voriconazole use but was increased with itraconazole use (AHR, 1.74; 95% CI, 1.27-2.37) or posaconazole use (AHR, 1.55; 95% CI, 1.00-2.41). CONCLUSIONS AND RELEVANCE: In this study, voriconazole use was associated with increased SCC risk among lung recipients, especially after prolonged exposure. Further research evaluating the risk-benefit ratio of shorter courses or alternative medications in transplant recipients at high risk for SCC should be considered.
- Published
- 2020
- Full Text
- View/download PDF
36. Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer
- Author
-
Engels, Eric A.
- Abstract
The advent in the last several years of effective immunotherapy for cancer has renewed interest in the role of the immune system in controlling cancer. The idea that the immune system can help control cancer has a long history. Solid organ transplant recipients (SOTRs) as well as human immunodeficiency virus (HIV)–infected people are affected by cell‐mediated immune dysfunction. Epidemiologic studies of these populations reveal a pattern characterized by a strongly increased incidence of virus‐related cancers (eg, Kaposi sarcoma, non‐Hodgkin lymphoma, and anogenital cancers). In addition, recent epidemiologic studies have evaluated cancer‐specific mortality among SOTRs and HIV‐infected people following a cancer diagnosis. For a wider range of cancers—not limited to those caused by viruses, and including melanoma and cancers of the colorectum, lung, and breast— these immunosuppressed cancer patients have higher cancer‐specific mortality than other cancer patients. This latter group of cancers somewhat mirrors those for which immunotherapy with checkpoint inhibitors is approved. These epidemiologic observations suggest that there are 2 distinct immune selection processes in humans: immunosurveillance directed against premalignant cells before cancer diagnosis (most relevant for preventing virus‐related cancers), and “immunocontainment” directed against established cancers. These processes thus appear relevant for different groups of malignancies and may have different mechanisms. The author summarizes epidemiologic studies of solid organ transplant recipients and HIV‐infected people, supporting an important role for the immune system in preventing and controlling cancer.
- Published
- 2019
- Full Text
- View/download PDF
37. Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes
- Author
-
Herr, Megan M., Schonfeld, Sara J., Dores, Graça M., Engels, Eric A., Tucker, Margaret A., Curtis, Rochelle E., and Morton, Lindsay M.
- Abstract
Infectious agents have been identified in the etiology of certain non-Hodgkin lymphoma (NHL) subtypes and solid tumors. The impact of this shared etiology on risk for second cancers in NHL survivors has not been comprehensively studied. We used US population–based cancer registry data to quantify risk of solid malignancies associated with infectious etiology among 127 044 adult 1-year survivors of the 4 most common NHL subtypes diagnosed during 2000 to 2014 (mean follow-up, 4.5-5.2 years). Compared with the general population, elevated risks for liver, stomach, and anal cancers were observed among diffuse large B-cell lymphoma (DLBCL) survivors (standardized incidence ratio [SIR], 1.85; 95% confidence interval [CI], 1.46-2.31; SIR, 1.51; 95% CI, 1.16-1.94; SIR, 3.71; 95% CI, 2.52-5.27, respectively) and marginal zone lymphoma (MZL; SIR, 1.98; 95% CI, 1.34-2.83; SIR, 2.78; 95% CI, 2.02-3.74; SIR, 2.36; 95% CI, 1.02-4.64, respectively) but not follicular lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma. Anal cancer risk was particularly elevated among DLBCL survivors with HIV (SIR, 68.34; 95% CI, 37.36-114.66) vs those without (SIR, 2.09; 95% CI, 1.22-3.34). The observed patterns are consistent with shared associations between these cancers and hepatitis C virus, Helicobacter pylori, and HIV, respectively. In contrast, risks for cervical and oropharyngeal/tonsil cancers were not elevated among survivors of any NHL subtype, possibly because of the lack of NHL association with human papillomavirus or population-wide screening practices (for cervical cancer). In summary, patterns of elevated second cancer risk differed by NHL subtype. Our results suggest shared infectious etiology has implications for subsequent cancer risks among DLBCL and MZL survivors, which may help inform surveillance for these survivors.
- Published
- 2019
- Full Text
- View/download PDF
38. Risk of lung cancer in lung transplant recipients in the United States
- Author
-
Triplette, Matthew, Crothers, Kristina, Mahale, Parag, Yanik, Elizabeth L., Valapour, Maryam, Lynch, Charles F., Schabath, Matthew B., Castenson, David, and Engels, Eric A.
- Abstract
Lung transplant recipients have an increased risk of lung cancer that is poorly understood. Prior studies are largely descriptive and single‐center, and have not examined risk factors or outcomes in this population. This registry‐linkage study utilized matched transplant and cancer registry data from 17 USstates/regions during 1987‐2012. We used standardized incidence ratios (SIRs) to compare incidence with the general population, Poisson models to identify lung cancer risk factors, and Cox models to compare survival after diagnosis. Lung cancer risk was increased among lung recipients (SIR4.8, 95% confidence interval [CI] 4.1‐5.5). Those with single lung transplant had 13‐fold (95% CI11‐15) increased risk in the native lung. Native lung cancer risk factors included age, prior smoking, time since transplant, and idiopathic pulmonary fibrosis. Compared with cases in the general population, lung cancers in recipients were more frequently localized stage (P = .02) and treated surgically (P= .05). However, recipients had higher all‐cause (adjusted hazard ratio 1.90, 95% CI1.52‐2.37) and cancer‐specific mortality (adjusted hazard ratio 1.67, 95% CI1.28‐2.18). In conclusion, lung cancer risk is increased after lung transplant, especially in the native lung of single lung recipients. Traditional risk factors are associated with lung cancer in these patients. Lung cancer survival is worse among lung recipients despite earlier diagnosis. In this registry‐linkage study using matched transplant and cancer registry data, the authors compare lung cancer risk, risk factors, stage, and survival between lung transplant recipients and the general population, demonstrating an elevated risk of lung cancer and poor survival among transplant recipients.
- Published
- 2019
- Full Text
- View/download PDF
39. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study
- Author
-
Hernández-Ramírez, Raúl U, Qin, Li, Lin, Haiqun, Leyden, Wendy, Neugebauer, Romain S, Althoff, Keri N, Achenbach, Chad J, Hessol, Nancy A, D'Souza, Gypsyamber, Gebo, Kelly A, Gill, M John, Grover, Surbhi, Horberg, Michael A, Li, Jun, Mathews, W Christopher, Mayor, Angel M, Park, Lesley S, Rabkin, Charles S, Salters, Kate, Justice, Amy C, Moore, Richard D, Engels, Eric A, Silverberg, Michael J, Dubrow, Robert, Betts, Adrian, Brooks, John T., Freeman, Aimee M., Van Rompaey, Stephen E., Burchell, Ann, Yip, Benita, You, Bin, Hogan, Brenna, Grasso, Chris, Hogg, Robert S., Benson, Constance A., Drozd, Daniel R., Sterling, Timothy R., Haas, David, Humes, Elizabeth, Crane, Heidi M., Willig, James, Eron, Joseph J., Martin, Jeffrey N., Saag, Michael S., Jing, Jerry, Zhang, Jinbing, Lindsay, Joanne, Hunter-Mellado, Robert F., Deeks, Steven G., Zhu, Julia, Montaner, Julio S.G., McReynolds, Justin, Gabler, Karyn, Buchacz, Kate, Rodriguez, Benigno, Thorne, Jennifer E., Margolick, Joseph B., Anastos, Kathryn, Jacobson, Lisa P., Klein, Marina B., Kroch, Abigail, Morton, Liz, Turner, Megan, Fiellin, David, Gange, Stephen J., Mugavero, Michael J., Harrigan, P. Richard, Rebeiro, Peter, Bosch, Ronald J., Kirk, Gregory D., Mayer, Kenneth H., McKaig, Rosemary G., Coburn, Sally, Napravnik, Sonia, Kitahata, Mari M., Lober, William B., and Lee, Jennifer S.
- Abstract
Research is needed to better understand relations between immunosuppression and HIV viraemia and risk for non-Hodgkin lymphoma, a common cancer in people living with HIV. We aimed to identify key CD4 count and HIV RNA (viral load) predictors of risk for non-Hodgkin lymphoma, overall and by subtype.
- Published
- 2019
- Full Text
- View/download PDF
40. Risk of lip cancer after solid organ transplantation in the United States
- Author
-
Laprise, Claudie, Cahoon, Elizabeth K., Lynch, Charles F., Kahn, Amy R., Copeland, Glenn, Gonsalves, Lou, Madeleine, Margaret M., Pfeiffer, Ruth M., and Engels, Eric A.
- Abstract
Solid organ transplant recipients have an increased risk of lip cancer, but the reasons are uncertain. Using data from the Transplant Cancer Match Study, we describe the epidemiology of lip cancer among 261 500 transplant recipients in the United States. Two hundred thirty‐one lip cancers were identified, corresponding to elevated risks for both invasive and in situ lip cancers (standardized incidence ratios of 15.3 and 26.2, respectively). Invasive lip cancer incidence was associated with male sex (adjusted incidence rate ratio [aIRR] 2.01, 95% CI 1.44‐2.82), transplanted organ (0.33, 0.20‐0.57, for liver transplants and 3.07, 1.96‐4.81, for lung transplants, compared with kidney transplants), and racial/ethnic groups other than non‐Hispanic whites (0.09, 0.04‐0.2). In addition, incidence increased with age and during the first 3 years following transplant, and was higher in recipients prescribed cyclosporine/azathioprine maintenance therapy (aIRR 1.79, 95% CI 1.09‐2.93, compared with use of tacrolimus/mycophenolate mofetil) and following a diagnosis of cutaneous squamous cell carcinoma (4.21, 2.69‐0.94). The elevation in lip cancer incidence is consistent with an effect of immunosuppression. Notably, the very strong associations with white race and history of prior skin cancer point to an important role for ultraviolet radiation exposure, and cyclosporine and azathioprine may contribute as photosensitizing or DNA damaging agents. The authors use data from the Transplant Cancer Match Study to describe the epidemiology of lip cancer among transplant recipients in the United States and bring new evidence to support ultraviolet radiation exposure as a strong risk factor.
- Published
- 2019
- Full Text
- View/download PDF
41. Trends in Human Immunodeficiency Virus Type 1 (HIV-1)-Load among HIV-1-Infected Children with Hemophilia
- Author
-
Engels, Eric A., Rosenberg, Philip S., Katki, Hormuzd, Goedert, James J., Biggar, Robert J., and Study, Hemophilia Cohort
- Subjects
HIV (Viruses) -- Physiological aspects ,Hemophilia in children -- Physiological aspects ,Virus research -- Analysis ,HIV patients -- Physiological aspects ,Health - Published
- 2001
42. Cancer Risk Following HLA-Incompatible Living Donor Kidney Transplantation
- Author
-
Motter, Jennifer D., Massie, Allan B., Garonzik-Wang, Jacqueline M., Pfeiffer, Ruth M., Yu, Kelly J., Segev, Dorry L., and Engels, Eric A.
- Published
- 2023
- Full Text
- View/download PDF
43. Plasma HIV Viral Load in Patients with Hemophilia and Late-Stage HIV Disease: A Measure of Current Immune Suppression
- Author
-
Engels, Eric A., Rosenberg, Philip S., O'Brien, Thomas R., and Goedert, James J.
- Subjects
HIV infection -- Development and progression ,Viremia -- Health aspects ,Health - Abstract
Background: For patients infected with HIV, plasma HIV viral load in early disease predicts long-term prognosis. However, the implications of viral load measurements late in HIV disease are uncertain. Objective: To evaluate the relation between plasma HIV viral load and subsequent risk for disease progression in patients with late-stage HIV disease. Design: Retrospective cohort study. Setting: 16 treatment centers for patients with hemophilia. Patients: 389 patients with hemophilia and late-stage HIV disease (CD4 count [is less than] 200 cells/[mm.sup.3]). Measurements: Plasma HIV viral load was measured at baseline. Patients were followed for AIDS-related illnesses (primary outcome) and, specifically, Pneumocystis carinii pneumonia (secondary outcome). Results: HIV viral load strongly predicted AIDS-related illness. For patients with viral loads less than 4.00 [log.sub.10] copies/mL, the 1-year actuarial risk was 0% and the 5-year risk was 25%. For patients with viral loads of at least 6.00 [log.sub.10] copies/mL, the 1-year actuarial risk was 42% and the 5-year risk was 78%. A linear relation existed between viral load and risk for AIDS-related illness (hazard ratio, 2.37 per [log.sub.10] copies/mL; P [is less than] 0.001). In addition, viral load most strongly predicted risk for illness immediately after viral load testing; this predictive relation attenuated over time (P = 0.002). These findings changed little after adjustment for CD4 cell counts that were updated during follow-up. In the first year after viral load was measured, it predicted occurrence of P. carinii pneumonia (hazard ratio, 4.69 per [log.sub.10] copies/mL; P [is less than] 0.001). Conclusions: In patients with hemophilia and late-stage HIV disease, viral load predicts disease progression independently of CD4 cell counts. Because viral load most strongly predicts progression immediately after load is measured, it seems to reflect the current level of immuno-suppression., Viral load can predict how fast HIV infection will progress, even in its later stages. Viral load means how much virus is present in the body. In study of 389 hemophiliacs with advanced HIV infection, the risk of AIDS-related illness and opportunistic infections was greater in those with higher viral levels. This was independent of their CD4 cell count.
- Published
- 1999
44. How to survive Ovie's shot
- Author
-
Engels, Eric
- Subjects
Goaltenders (Hockey) -- Interviews ,General interest ,Montreal Canadiens -- Officials and employees - Abstract
The Washington Capitals are cycling the puck on the power play and it ends up on the stick of Alex Ovechkin, who has a little bit of daylight. In a [...]
- Published
- 2016
45. Cancer burden attributable to cigarette smoking among HIV-infected people in North America
- Author
-
Altekruse, Sean F., Shiels, Meredith S., Modur, Sharada P., Land, Stephanie R., Crothers, Kristina A., Kitahata, Mari M., Thorne, Jennifer E., Mathews, William C., Fernández-Santos, Diana M., Mayor, Angel M., Gill, John M., Horberg, Michael A., Brooks, John T., Moore, Richard D., Silverberg, Michael J., Althoff, Keri N., and Engels, Eric A.
- Published
- 2018
- Full Text
- View/download PDF
46. Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients
- Author
-
Mahale, Parag, Shiels, Meredith S., Lynch, Charles F., and Engels, Eric A.
- Abstract
Primary central nervous system lymphoma (PCNSL) risk is greatly increased in immunosuppressed human immunodeficiency virus–infected people. Using data from the UStransplant registry linked with 17 cancer registries (1987‐2014), we studied PCNSLand systemic non‐Hodgkin lymphoma (NHL) in 288 029 solid organ transplant recipients. Transplant recipients had elevated incidence for PCNSLcompared with the general population (standardized incidence ratio = 65.1; N = 168), and this elevation was stronger than for systemic NHL(standardized incidence ratio=11.5; N = 2043). Compared to kidney recipients, PCNSLincidence was lower in liver recipients (adjusted incidence rate ratio [aIRR] = 0.52), similar in heart and/or lung recipients, and higher in other/multiple organ recipients (aIRR= 2.45). PCNSLincidence was higher in Asians/Pacific Islanders than non‐Hispanic whites (aIRR= 2.09); after induction immunosuppression with alemtuzumab (aIRR= 3.12), monoclonal antibodies (aIRR= 1.83), or polyclonal antibodies (aIRR= 2.03); in recipients who were Epstein‐Barr virus–seronegative at the time of transplant and at risk of primary infection (aIRR= 1.95); and within the first 1.5 years after transplant. Compared to other recipients, those with PCNSLhad increased risk of death (adjusted hazard ratio [aHR] = 11.79) or graft failure/retransplantation (aHR= 3.24). Recipients with PCNSLalso had higher mortality than those with systemic NHL(aHR= 1.48). In conclusion, PCNSLrisk is highly elevated among transplant recipients, and it carries a poor prognosis. In a large population‐based cohort study of solid organ transplant recipients, risk of primary central nervous system lymphoma was substantially elevated, especially within the first 1.5 years after transplant and in recipients who were seronegative for Epstein–Barr virus infection, and the diagnosis was associated with higher mortality than other systemic non‐Hodgkin lymphomas.
- Published
- 2018
- Full Text
- View/download PDF
47. Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States
- Author
-
Gupta, Gaurav, Kuppachi, Sarat, Kalil, Roberto S., Buck, Christopher B., Lynch, Charles F., and Engels, Eric A.
- Abstract
Recent case series describe detection of BKpolyomavirus (BKV) in urinary tract cancers in kidney transplant recipients, suggesting that BKVcould contribute to the development of these cancers. We assessed risk for urinary tract cancers in kidney recipients with or without treatment for presumed BKVnephropathy (tBKVN) using data from the United States Transplant Cancer Match Study (2003‐2013). Among 55 697 included recipients, 2015 (3.6%) were reported with tBKVN. Relative to the general population, incidence was similarly elevated (approximately 4.5‐fold) for kidney cancer in recipients with or without tBKVN, and incidence was not increased in either group for prostate cancer. In contrast, for invasive bladder cancer, incidence was more strongly elevated in recipients with versus without tBKVN(standardized incidence ratios 4.5 vs. 1.7; N = 48 cases), corresponding to an incidence rate ratio (IRR) of 2.9 (95%confidence interval [CI]1.0‐8.2), adjusted for sex, age, transplant year, and use of polyclonal antibody induction. As a result, recipients with tBKVNhad borderline increased incidence for all urothelial cancers combined (renal pelvis, ureter, and bladder cancers: adjusted IRR2.2, 95% CI0.9‐5.4; N = 89 cases). Together with reports describing BKVdetection in tumor tissues, these results support an association between BKVand urothelial carcinogenesis among kidney transplant recipients. In this study of 55,697 kidney recipients in the United States, the authors demonstrate a 2.9‐fold elevation in the incidence of bladder cancer following reported treatment for BK polyomavirus nephropathy, suggesting that BK virus may contribute to bladder carcinogenesis.
- Published
- 2018
- Full Text
- View/download PDF
48. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection
- Author
-
Mahale, Parag, Engels, Eric A, Li, Ruosha, Torres, Harrys A, Hwang, Lu-Yu, Brown, Eric L, and Kramer, Jennifer R
- Abstract
Background and aimChronic HCV infection is associated with several extrahepatic manifestations (EHMs). Data on the effect of sustained virological response (SVR) on the risk of EHMs are limited.MethodsWe conducted a retrospective cohort study using data of patients from the US Veterans Affairs HCV Clinical Case Registry who had a positive HCV RNA test (10/1999-08/2009). Patients receiving interferon-based antiviral therapy (AVT) were identified. SVR was defined as negative HCV RNA at least 12 weeks after end of AVT. Risks of eight incident EHMs were evaluated in Cox regression models.ResultsOf the 160 875 HCV-infected veterans, 31 143 (19.4%) received AVT, of whom 10 575 (33.9%) experienced SVR. EHM risk was reduced in the SVR group compared with untreated patients for mixed cryoglobulinaemia (adjusted HR (aHR)=0.61; 95% CI 0.39 to 0.94), glomerulonephritis (aHR=0.62; 95% CI 0.48 to 0.79), porphyria cutanea tarda (PCT) (aHR=0.41; 95% CI 0.20 to 0.83), non-Hodgkin’s lymphoma (NHL) (aHR=0.64; 95% CI 0.43 to 0.95), diabetes (aHR=0.82; 95% CI 0.76 to 0.88) and stroke (aHR=0.84; 95% CI 0.74 to 0.94), but not for lichen planus (aHR=1.11; 95% CI 0.78 to 1.56) or coronary heart disease (aHR=1.12; 95% CI 0.81 to 1.56). Risk reductions were also observed when patients with SVR were compared with treated patients without SVR for mixed cryoglobulinaemia, glomerulonephritis, PCT and diabetes. Significant reductions in the magnitude of aHRs towards the null with increasing time to initiation of AVT after HCV diagnosis were observed for glomerulonephritis, NHL and stroke.ConclusionsRisks of several EHMs of HCV infection are reduced after AVT with SVR. However, early initiation of AVT may be required to reduce the risk of glomerulonephritis, NHL and stroke.
- Published
- 2018
- Full Text
- View/download PDF
49. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study
- Author
-
Hernández-Ramírez, Raúl U, Shiels, Meredith S, Dubrow, Robert, and Engels, Eric A
- Abstract
Monitoring cancer risk among HIV-infected people in the modern antiretroviral therapy (ART) era is essential given their elevated risk for many cancers and prolonged survival with immunosuppression, ART exposure, and ageing. We aimed to examine cancer risk in HIV-infected people in the USA as compared with that in the general population.
- Published
- 2017
- Full Text
- View/download PDF
50. Risk of Nonkeratinocyte Skin Cancers in People Living with HIV during the Era of Antiretroviral Therapy
- Author
-
Luu, Yen T., Luo, Qianlai, Horner, Marie-Josephe, Shiels, Meredith, Engels, Eric A., and Sargen, Michael R.
- Abstract
Antiretroviral therapy may alter susceptibility to nonkeratinocyte skin cancers (NKSCs) by improving immunity in people living with HIV. Using linked data from HIV and cancer registries in 12 states/regions in the United States during the antiretroviral therapy era (1996‒2018), we calculated standardized incidence ratios for 27 NKSCs, comparing incidence with that of the general population. Risk factors for NKSCs were evaluated using Poisson regression. There were 2,743 NKSCs diagnosed in 585,706 people living with HIV followed for 4,575,794 person-years. Kaposi sarcoma was the most common cancer (82%), followed by melanoma (12%) and cutaneous lymphoma (2.6%). Incidence was elevated for virus-related NKSCs: Kaposi sarcoma (standardized incidence ratio = 147, 95% confidence interval = 141‒153), diffuse large B-cell lymphoma (standardized incidence ratio = 5.19, 95% confidence interval = 3.13‒8.11), and Merkel cell carcinoma (standardized incidence ratio = 3.15, 95% confidence interval = 1.93‒4.87); elevated incidence for diffuse large B-cell lymphoma and Merkel cell carcinoma was observed only among people living with HIV with a previously acquired immunodeficiency syndrome diagnosis. Kaposi sarcoma risk was highest among men who have sex with men. Incidence was not increased for melanoma, adnexal carcinomas, and sarcomas. Melanoma and Merkel cell carcinoma arose disproportionately on sun-exposed skin, supporting a role for UVR in their development. In conclusion, risk for most NKSCs was similar to that of the general population during the antiretroviral therapy era, suggesting that people living with HIV without NKSC risk factors may not require intensive skin surveillance.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.